Advertisement

Journal of Molecular Neuroscience

, Volume 60, Issue 3, pp 316–324 | Cite as

The Neurobiology and Age-Related Prevalence of the ε4 Allele of Apolipoprotein E in Alzheimer’s Disease Cohorts

  • Amy L. Heffernan
  • Cameron Chidgey
  • Po Peng
  • Colin L. Masters
  • Blaine R. Roberts
Article

Abstract

Alzheimer’s disease (AD) is a progressive neurodegenerative disease characterised by amyloid beta (Aβ) plaques and tau neurofibrillary tangles in the brain. Human apolipoprotein E (ApoE) is a lipid transport protein coded by the polymorphic APOE gene, with three major alleles: ε2, ε3 and ε4. After age, the ε4 allele is the greatest risk factor for developing sporadic AD, conferring an increased risk of 3–4 and 8–12 times for one or two copies of the allele, respectively. This risk is reported to vary by demographic factors including sex, ethnicity and geography. In order to understand the risk of ApoE ε4 in relation to age, the primary risk factor for developing AD, we need to understand how the prevalence of APOE genotypes changes with age. Here, we present the first data on age-related prevalence of APOE ε4 in AD in three AD cohorts in Australia and the USA. There is a significant association between age and ε4 prevalence, particularly for ε4 homozygotes, such that as age increases the prevalence of ε4 decreases. Further studies on a random, population-based sample of the population are needed to provide more generalizable data, particularly in the >90-year-old age group.

Keywords

Alzheimer’s disease APOE Apolipoprotein E Population demographics 

Notes

Acknowledgments

The authors gratefully acknowledge Simone Wilk, Chris Fowler and James Doecke for assistance with data retrieval; Oliver Thomas for advice on statistical analysis and Laura Cortes Castrillon for assistance with PyMol. ALH is funded by a Dementia Research Development Fellowship (APP1106911); PP is funded by an Australian Postgraduate Award and an International Postgraduate Research Scholarship. We wish to thank ADNI, AIBL and the National Alzheimer’s Coordinating Centre including all investigators, participants and their families. A complete list of principle investigators and funding sources can be found in the Supplementary Material. The Florey Institute acknowledges the strong support from the Victorian Government and in particular the funding from the Operational Infrastructure Support Grant.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Supplementary material

12031_2016_804_MOESM1_ESM.docx (29 kb)
ESM 1 (DOCX 29 kb)

References

  1. ABS (2014). Australian Bureau of Statistics. Causes of Death, Australia 2012. ABS cat. no. 3303.0. Canberra:ABS.Google Scholar
  2. ALZGENE (2010). Meta-analysis of all published AD association studies (case-control only) APOE_E2/3/4. Available from http://www.alzgene.org/meta.asp?geneID=83. Date accessed: 9 March 2016.
  3. Bang OY, Kwak YT, Joo IS, Huh K (2003) Important link between dementia subtype and apolipoprotein E: a meta-analysis. Yonsei Med J 44:401–413CrossRefPubMedGoogle Scholar
  4. Castellano JM, Kim J, Stewart FR, et al. (2011) Human apoE isoforms differentially regulate brain amyloid-beta peptide clearance. Sci Transl Med 3:89ra57CrossRefPubMedPubMedCentralGoogle Scholar
  5. Chen J, Li Q, Wang J (2011) Topology of human apolipoprotein E3 uniquely regulates its diverse biological functions. Proc Natl Acad Sci U S A 108:14813–14818CrossRefPubMedPubMedCentralGoogle Scholar
  6. Corder EH, Saunders AM, Risch NJ, et al. (1994) Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet 7:180–184CrossRefPubMedGoogle Scholar
  7. Corder EH, Saunders AM, Strittmatter WJ, et al. (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 261:921–923CrossRefPubMedGoogle Scholar
  8. Cramer PE, Cirrito JR, Wesson DW, et al. (2012) ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models. Science 335:1503–1506CrossRefPubMedPubMedCentralGoogle Scholar
  9. Das HK, McPherson J, Bruns GA, Karathanasis SK, Breslow JL (1985) Isolation, characterization, and mapping to chromosome 19 of the human apolipoprotein E gene. J Biol Chem 260:6240–6247PubMedGoogle Scholar
  10. Davignon J, Gregg RE, Sing CF (1988) Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis 8:1–21CrossRefPubMedGoogle Scholar
  11. Deloukas P, Kanoni S, Willenborg C, et al. (2013) Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet 45:25–33CrossRefPubMedGoogle Scholar
  12. Eichner JE, Dunn ST, Perveen G, Thompson DM, Stewart KE, Stroehla BC (2002) Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review. Am J Epidemiol 155:487–495CrossRefPubMedGoogle Scholar
  13. Eisenberg DT, Kuzawa CW, Hayes MG (2010) Worldwide allele frequencies of the human apolipoprotein E gene: climate, local adaptations, and evolutionary history. Am J Phys Anthropol 143:100–111CrossRefPubMedGoogle Scholar
  14. El-Lebedy D, Raslan HM, Mohammed AM (2016) Apolipoprotein E gene polymorphism and risk of type 2 diabetes and cardiovascular disease. Cardiovasc Diabetol 15:12CrossRefPubMedPubMedCentralGoogle Scholar
  15. Ellis KA, Bush AI, Darby D, et al. (2009) The Australian imaging, biomarkers and lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease. Int Psychogeriatr 21:672–687CrossRefPubMedGoogle Scholar
  16. Elosua R, Ordovas JM, Cupples LA, et al. (2004) Association of APOE genotype with carotid atherosclerosis in men and women: the Framingham Heart Study. J Lipid Res 45:1868–1875CrossRefPubMedGoogle Scholar
  17. Farrer LA, Cupples LA, Haines JL, et al. (1997) Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis APOE and Alzheimer Disease Meta Analysis Consortium JAMA 278:1349–1356PubMedGoogle Scholar
  18. Farrer LA, Cupples LA, van Duijn CM, et al. (1995) Apolipoprotein E genotype in patients with Alzheimer’s disease: implications for the risk of dementia among relatives. Ann Neurol 38:797–808CrossRefPubMedGoogle Scholar
  19. Frieden C, Garai K (2013) Concerning the structure of apoE. Protein Sci 22:1820–1825CrossRefPubMedPubMedCentralGoogle Scholar
  20. Garai K, Verghese PB, Baban B, Holtzman DM, Frieden C (2014) The binding of apolipoprotein E to oligomers and fibrils of amyloid-beta alters the kinetics of amyloid aggregation. Biochemistry 53:6323–6331CrossRefPubMedPubMedCentralGoogle Scholar
  21. Giau VV, Bagyinszky E, An SSA, Kim SY (2015) Role of apolipoprotein E in neurodegenerative diseases. Neuropsychiatr Dis Treat 11:1723–1737CrossRefPubMedPubMedCentralGoogle Scholar
  22. Golabek AA, Soto C, Vogel T, Wisniewski T (1996) The interaction between apolipoprotein E and Alzheimer's amyloid beta-peptide is dependent on beta-peptide conformation. J Biol Chem 271:10602–10606CrossRefPubMedGoogle Scholar
  23. Havel RJ, Kane JP (1973) Primary dysbetalipoproteinemia: predominance of a specific apoprotein species in triglyceride-rich lipoproteins. Proc Natl Acad Sci U S A 70:2015–2019CrossRefPubMedPubMedCentralGoogle Scholar
  24. Holtzman DM, Bales KR, Tenkova T, et al. (2000) Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 97:2892–2897CrossRefPubMedPubMedCentralGoogle Scholar
  25. Holtzman DM, Herz J, Bu G (2012) Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. Cold Spring Harbor Perspectives in Medicine 2:a006312PubMedPubMedCentralGoogle Scholar
  26. Huang Y (2010) Mechanisms linking apolipoprotein E isoforms with cardiovascular and neurological diseases. Curr Opin Lipidol 21:337–345CrossRefPubMedGoogle Scholar
  27. Innerarity TL, Friedlander EJ, Rall SC, Weisgraber KH, Mahley RW (1983) The receptor-binding domain of human apolipoprotein E. Binding of apolipoprotein E fragments Journal of Biological Chemistry 258:12341–12347PubMedGoogle Scholar
  28. Jiang Q, Lee CYD, Mandrekar S, et al. (2008) ApoE promotes the proteolytic degradation of Aβ. Neuron 58:681–693CrossRefPubMedPubMedCentralGoogle Scholar
  29. Keene CD, Cudaback E, Li X, Montine KS, Montine TJ (2011) Apolipoprotein E isoforms and regulation of the innate immune response in brain of patients with Alzheimer’s disease. Curr Opin Neurobiol 21:920–928CrossRefPubMedPubMedCentralGoogle Scholar
  30. Kim J, Basak JM, Holtzman DM (2009) The role of apolipoprotein E in Alzheimer’s disease. Neuron 63:287–303CrossRefPubMedPubMedCentralGoogle Scholar
  31. Kim J, Jiang H, Park S, et al. (2011) Haploinsufficiency of human APOE reduces amyloid deposition in a mouse model of amyloid-beta amyloidosis. J Neurosci 31:18007–18012CrossRefPubMedPubMedCentralGoogle Scholar
  32. Kim J, Yoon H, Basak J, Kim J (2014) Apolipoprotein E in synaptic plasticity and Alzheimer’s disease: potential cellular and molecular mechanisms. Mol Cells 37:767–776CrossRefPubMedPubMedCentralGoogle Scholar
  33. LaDu MJ, Falduto MT, Manelli AM, Reardon CA, Getz GS, Frail DE (1994) Isoform-specific binding of apolipoprotein E to beta-amyloid. J Biol Chem 269:23403–23406PubMedGoogle Scholar
  34. Lim, Y. Y., Laws, S. M., Villemagne, V. L., et al. (2016). A beta-related memory decline in APOE epsilon4 noncarriers: implications for Alzheimer disease. Neurology.Google Scholar
  35. Liu CC, Kanekiyo T, Xu H, Bu G (2013) Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol 9:106–118CrossRefPubMedPubMedCentralGoogle Scholar
  36. Louhija J, Miettinen HE, Kontula K, Tikkanen MJ, Miettinen TA, Tilvis RS (1994) Aging and genetic variation of plasma apolipoproteins. Relative loss of the apolipoprotein E4 phenotype in centenarians. Arterioscler Thromb 14:1084–1089CrossRefPubMedGoogle Scholar
  37. Mahley RW, Rall SC Jr (2000) Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet 1:507–537CrossRefPubMedGoogle Scholar
  38. Mahley RW, Weisgraber KH, Huang Y (2006) Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer’s disease. Proc Natl Acad Sci U S A 103:5644–5651CrossRefPubMedPubMedCentralGoogle Scholar
  39. Mahley RW, Weisgraber KH, Huang Y (2009) Apolipoprotein E: structure determines function, from atherosclerosis to Alzheimer’s disease to AIDS. J Lipid Res 50:S183–S188CrossRefPubMedPubMedCentralGoogle Scholar
  40. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K (1985) Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A 82:4245–4249CrossRefPubMedPubMedCentralGoogle Scholar
  41. Mayila W, Fang MW, Cheng ZH, Qiu CC (2005) Polymorphism of apolipoprotein E gene and natural longevity in the Xinjiang Uighur people: an association study. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 22:462–463PubMedGoogle Scholar
  42. Mohamad, E. H., Antoine, P., Amouyel, P., Lambert, J. C., Pasquier, F. and Kapogiannis, D. (2016). Apolipoprotein E (APOE) epsilon4 and episodic memory decline in Alzheimer’s disease: A review. Ageing Res Rev.Google Scholar
  43. Mozaffarian D, Benjamin EJ, Go AS, et al. (2016) Executive Summary: Heart Disease and Stroke Statistics—2016 update: a report from the American Heart Association. Circulation 133:447–454CrossRefPubMedGoogle Scholar
  44. Nolte RT, Atkinson D (1992) Conformational analysis of apolipoprotein A-I and E-3 based on primary sequence and circular dichroism. Biophys J 63:1221–1239CrossRefPubMedPubMedCentralGoogle Scholar
  45. OMIM (2016). Online ‘Mendelian Inheritance in Man’ (OMIM) Apolipoprotein E; APOE -107741. Available from https://omim.org/entry/107741. Date accessed: 9 March 2016.
  46. Pietrzak RH, Lim YY, Ames D, et al. (2015) Trajectories of memory decline in preclinical Alzheimer's disease: results from the Australian Imaging, Biomarkers and Lifestyle Flagship Study of ageing. Neurobiol Aging 36:1231–1238CrossRefPubMedGoogle Scholar
  47. Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP (2013) The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement 9:63–75.e62CrossRefPubMedGoogle Scholar
  48. R Core Team (2015) R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL http://www.R-project.org/.
  49. Ryu S, Atzmon G, Barzilai N, Raghavachari N, Suh Y (2016) Genetic landscape of APOE in human longevity revealed by high-throughput sequencing. Mech Ageing Dev 155:7–9CrossRefPubMedGoogle Scholar
  50. Schachter F, Faure-Delanef L, Guenot F, et al. (1994) Genetic associations with human longevity at the APOE and ACE loci. Nat Genet 6:29–32CrossRefPubMedGoogle Scholar
  51. Shore VG, Shore B (1973) Heterogeneity of human plasma very low density lipoproteins. Separation of species differing in protein components Biochemistry 12:502–507PubMedGoogle Scholar
  52. Singh PP, Singh M, Mastana SS (2006) APOE distribution in world populations with new data from India and the UK. Ann Hum Biol 33:279–308CrossRefPubMedGoogle Scholar
  53. Sparrow JT, Sparrow DA, Fernando G, Culwell AR, Kovar M, Gotto AM (1992) Apolipoprotein E: phospholipid binding studies with synthetic peptides from the carboxyl terminus. Biochemistry 31:1065–1068CrossRefPubMedGoogle Scholar
  54. Strittmatter WJ, Weisgraber KH, Huang DY, et al. (1993) Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci U S A 90:8098–8102CrossRefPubMedPubMedCentralGoogle Scholar
  55. Sweet RA, Seltman H, Emanuel JE, et al. (2012) Effect of Alzheimer’s disease risk genes on trajectories of cognitive function in the Cardiovascular Health Study. Am J Psychiatry 169:954–962CrossRefPubMedPubMedCentralGoogle Scholar
  56. Tai LM, Ghura S, Koster KP, et al. (2015) APOE-modulated Abeta-induced neuroinflammation in Alzheimer's disease: current landscape, novel data, and future perspective. J Neurochem 133:465–488CrossRefPubMedPubMedCentralGoogle Scholar
  57. Todd S, Barr S, Roberts M, Passmore AP (2013) Survival in dementia and predictors of mortality: a review. Int J Geriatr Psychiatry 28:1109–1124PubMedGoogle Scholar
  58. Tombaugh TN, McIntyre NJ (1992) The mini-mental state examination: a comprehensive review. J Am Geriatr Soc 40:922–935Google Scholar
  59. Verghese PB, Castellano JM, Holtzman DM (2011) Apolipoprotein E in Alzheimer’s disease and other neurological disorders. Lancet Neurol 10:241–252CrossRefPubMedPubMedCentralGoogle Scholar
  60. Visvikis-Siest S, Marteau JB (2006) Genetic variants predisposing to cardiovascular disease. Curr Opin Lipidol 17:139–151CrossRefPubMedGoogle Scholar
  61. Weisgraber KH, Innerarity TL, Mahley RW (1982) Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to cysteine-arginine interchange at a single site. J Biol Chem 257:2518–2521PubMedGoogle Scholar
  62. Weller RO, Hawkes CA, Kalaria RN, Werring DJ, Carare RO (2015) White matter changes in dementia: role of impaired drainage of interstitial fluid. Brain Pathol 25:63–78CrossRefPubMedGoogle Scholar
  63. WHO (2011). Global Atlas on cardiovascular disease prevention and control. Edited by Mendis S, Puska P and Norrving B. World Health Organisation, Geneva. Available from: http://www.who.int/cardiovascular_diseases/publications/atlas_cvd/en/.
  64. Wilson C, Wardell M, Weisgraber K, Mahley R, Agard D (1991) Three-dimensional structure of the LDL receptor-binding domain of human apolipoprotein E. Science 252:1817–1822CrossRefPubMedGoogle Scholar
  65. Zannis VI, Kardassis D, Zanni EE (1993) Genetic mutations affecting human lipoproteins, their receptors, and their enzymes. Adv Hum Genet 21:145–319PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • Amy L. Heffernan
    • 1
  • Cameron Chidgey
    • 2
  • Po Peng
    • 3
  • Colin L. Masters
    • 1
  • Blaine R. Roberts
    • 1
    • 4
  1. 1.University of Melbourne, The Florey Institute of Neuroscience and Mental HealthParkvilleAustralia
  2. 2.Faculty of Medicine, Dentistry and Health SciencesUniversity of MelbourneParkvilleAustralia
  3. 3.School of BiosciencesUniversity of MelbourneParkvilleAustralia
  4. 4.Cooperative Research Centre for Mental HealthParkvilleAustralia

Personalised recommendations